Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tajikistan Health News.
Press releases published on August 14, 2025

CRB Expands Life Sciences Leadership Team with Appointment of Senior Director Eric Hanson
Kansas City, Mo., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CRB, a leading provider of sustainable engineering, architecture, construction, and consulting services for the life sciences and food and beverage industries, today announced the appointment of Eric …

EvolveImmune Therapeutics Announces FDA Clearance of Investigational New Drug Application for EVOLVE104, a Novel Trispecific T Cell Engager with Integrated CD2 Costimulation
First Program from EVOLVE T-Cell Engager Platform to Advance into Clinical Development Phase 1 Clinical Trial of EVOLVE104 to be Initiated in 2025 BRANFORD, Conn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company …

Evoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update
SOLANA BEACH, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI® (metoclopramide) nasal spray, today reported …

Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
PITTSBURGH, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory …

Microbix Reports Results for Q3 Fiscal 2025
MISSISSAUGA, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and nine months of fiscal 2025 ended June 30, …

MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and …

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
– WTX-124 Phase 1/1b clinical trial on track for interim data readout in the fourth quarter of 2025, including patients in both the monotherapy and combination expansion arms of cutaneous melanoma and renal cell carcinoma – – Planning to engage with U.S. …

Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented results from its Phase 1 …

Larimar Therapeutics Reports Second Quarter 2025 Financial Results
Initial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025 Adolescent participants from the PK run-in study and patients with FA who have not participated in prior nomlabofusp …

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) …

Balt USA Responds to Patent Infringement Lawsuit Filed by Route 92 Medical
IRVINE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Balt USA, LLC (“Balt”), a global leader in neurovascular medical devices, today announced it intends to vigorously defend against the allegations of patent infringement filed by Route 92 Medical, Inc. …

Lungpacer Announces CMS NTAP Approval for AeroPace® System in FY2026 IPPS Final Rule
Exton, Pa., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Lungpacer Medical Inc., a medical technology company focused on neurostimulation therapies for critically ill patients, today announced that the Centers for Medicare …

Tilray Brands Reconfirms Strategy to Regain Nasdaq Compliance; Requests Extension to Meet Listing Requirements
NEW YORK and LEAMINGTON, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle consumer packaged goods company at the forefront of the cannabis, beverage, and wellness …

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial clinical activity by year end 2025 Phase 1 study of …

atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinic Reported positive topline data from the core, blinded stage of the …

Denovo Biopharma LLC to Participate in Upcoming Investor Events
SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative drugs, today announced that company management will participate in upcoming August and September investor events. The …

SEED Therapeutics Named Finalist for 2025 Prix Galien USA “Best Start-Up” Award
Nomination recognizes SEED’s pioneering work in molecular glue development in targeted protein degradation to address high unmet medical needs Follows recent FDA IND clearance for SEED’s lead asset RBM39 degrader ST-01156 KING OF PRUSSIA, Pa., Aug. 14, …

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights
Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratutrelvir, a ritonavir-free, protease inhibitor regimen in …

SRx Health Solutions Announces the Cancellation of Approximately 18.8 Million Shares of its Capital Stock
TAMPA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”), a leading global health and wellness company, today announced that further to the previously disclosed grant of an Initial Order under the …

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 – – On track to dose first participant in Phase 1 clinical trial for SL-325 in Q3 2025 – – Cash …